Jasper is a biotechnology company focused on developing and commercializing safer, more effective conditioning agents to allow for expanded use of curative therapy with stem cell transplantation and gene therapies. Our lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation.
Jasper Therapeutics was founded by Dr. Judith Shizuru, a Stanford professor, and Dr. Susan Prohaska, a Stanford-trained scientist and drug developer, with the goal of bringing curative hematopoietic cell transplantation to more people by making it safer and more effective. Jasper unites technologies from Stanford University and Amgen with cutting-edge science and expertise in hematopoietic cell transplantation, stem cell biology, oncology, and drug development. Building on niche-clearing technology from Stanford and with our lead compound JSP191, Dr. Shizuru initiated a clinical program funded by the California Institute for Regenerative Medicine (CIRM) to safely condition patients with severe combined immunodeficiency (SCID) prior to hematopoietic cell transplantation.